Thermo Fisher Scientific inked a deal with Janssen Biotech, part of Johnson & Johnson, to co-develop a companion diagnostic for cancer. The diagnostic test will support global clinical trial enrollment.
Oncology Innovation A Q&A with Kantar’s Stephanie Hawthorne, Vice President of Oncology and Specialty Therapeutics Oncology is one of the most exciting areas in healthcare today, as novel therapies continue to emerge that move forward our molecular understanding of the disease and offer effective treatment advances. In 2019, there were a variety of key developments […]
Roche Group member Genentech announced that the U.S. Food and Drug Administration accepted the company’s supplemental Biologics License Application and granted Priority Review for Tecentriq (atezolizumab) as a first-line monotherapy for people with advanced non-squamous and squamous non-small cell lung cancer without EGFR or ALK mutations with high PD-L1 expression, as determined by PD-L1 biomarker testing.
Treatment with Stelara is resulting in positive outcomes for patients with Crohn’s disease, as Janssen Pharmaceutical said 79% of patients in a late-stage trial showed a clinical response to the medication and 67% were in clinical remission.
As the J.P. Morgan Healthcare Conference entered the final day for 2020, a few topics rose to the top as trending, including the relative lack of big deals.
J&J’s Janssen received a grant from Food Allergy Research & Education (FARE) to help discover and validate biomarkers to boost research into food allergies and potentially develop therapies.
Companies from across the globe provide updates on their business and pipeline progress.
Shares of U.K.-based NuCana were down more than 21 percent after the company announced suspended enrollment of patients in a late-stage pancreatic cancer study.
Researchers at Rutgers University-New Brunswick recently published research about a nanotechnology platform that helps identify what happens to specific stem cells.
Shares of Texas-based Lexicon Pharmaceuticals shot up after the company announced positive 52-week cardiorenal data from a pooled analysis of the type 1 diabetes trials Tandem1 and Tandem2.